Radioactive 'Smart Bombs' target Hard-to-Treat cancers
NCT ID NCT07661641
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding to standard therapies. The study aims to find safe doses and check how the drugs spread in the body, using a third diagnostic agent to identify GRPR-positive tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium-177 and Actinium-225 attached to a molecule that targets GRPR
What this could lead to
If successful, this could provide a new targeted radiation therapy option for people with advanced GRPR-positive cancers that have stopped responding to standard treatments.
What could go wrong
This is a very early (Phase 1) trial, so the main goal is safety and dosing, not yet proving effectiveness. The radioactive drugs may cause side effects in healthy organs, and the trial is small, so results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GenesisCare Murdoch
NOT_YET_RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Melbourne Theranostic Innovation Center
RECRUITINGMelbourne N., Victoria, 3051, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact